论文部分内容阅读
介绍了吡虫啉与阿维菌素混配的一种新剂型——3.3%微乳剂,简述了该剂型的特点、配方选择、贮藏稳定性等实验结果,表明该微乳剂具有贮藏稳定性好、成本低、使用安全,具有良好开发前景。
A new formulation of imidacloprid and avermectin, 3.3% microemulsion, was introduced. The characteristics of the formulation, formulation selection and storage stability were described. The results showed that the microemulsion possesses good storage stability, Low cost, safe to use, with good development prospects.